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ABSTRACT 
The aim of the present study is to determine the Pakistani market condition for the healthcare of patients suffering from different pain condition e.g. arthritis, and also to 
correlate the quality with the cost of the brands. The present study is concerned to scrutinize and compare the physicochemical equivalence of different brands of sustained 
release tablets containing Diclofenac sodium purchased from different retail pharmacy outlets. The physicochemical equivalence of five different brands of Diclofenac sodium 
SR tablets was evaluated. These brands were tested through different statistical methods in accordance to the guidelines given in BP i.e. Weight variation, diameter, thickness, 
hardness, friability, dissolution, assay, price, expiry and appearance. Only two brands passed the dissolution test, one brand tablets were completely dissolved within first two 
hrs and remaining brands fail the dissolution test. Similarly problem was found in thickness of the different brands tablet. However no major problem was found in tablet weight 
variation, assay, diameter, friability, hardness parameter.  
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INTRODUCTION 
The  increase  in  the  number  of  generic  drug  products  has  placed 
health  care  people  to  select  one  from  among  several  seemingly 
equivalent products
2. For instance, in 1975 approximately 9% of all 
prescription  drugs  dispensed  in  the  United  States  were  generic 
versions
2. This figure rose to 20% in 1984 and 40% in 1991
1.Over 
80%  of  the  approximately  10,000  prescription  drugs  available  in 
1990 were obtained from more than one source and variable clinical 
responses  to  these  dosage  forms  supplied  by  two  or  more  drug 
manufacturers is documented. These variable responses may be due 
to  formulation,  packaging  and  storage  and  even  the  rigors  of  in-
process quality control. Pakistan as a developing country  offers a 
growing market for pharmaceuticals. All categories of the products 
are  the  research  product  of  multinational  firm  which  are 
reformulated  and  marked  by  these  national  firms.    Moreover  the 
multinational  firms  claim  that  their  high  price  are  due  to  the 
overheads  like  research,  high  salaries  of  employee,  maintaining 
GMP, GLP plus importing raw material from mother plants. The 
national firm claims that their products are not at all inferior to the 
products of multinational firm. It was in view of this fact that the 
W.H.O issued guidelines for global standard and requirements for 
the  registration,  assessment,  marketing,  authorization  and  quality 
control  of  generic  pharmaceutical  products
4.  Preliminary 
physicochemical assessment of the products is very important and in 
vitro dissolution testing can be a valuable predictor of the in vivo 
bioavailability and bioequivalence of oral solid dosage forms
2,3. 
To  produce  significant  sustaining  effects  and  to  increase  the 
bioavailability  of  drug, the  Modified  Release  (MR)  dosage  forms 
have  made  significant  progress  in  terms  of  clinical  efficacy  and 
patient compliance. The degree of precision of control over the rate 
of  drug  release  from  MR  dosage  from  varies  according  to  the 
particular formulating techniques employed
5. It is necessary to have 
comparative  bioavailability  of  conventional  (IR)  as  well  as  SR 
formulations
6,7.  
Diclofenac sodium (DS) is administered orally in the treatment of 
rheumatoid  arthritis,  osteoarthritis  and  also  for  a  variety  of 
nonrheumatic inflammatory conditions
8. It has short biological half-
life  and  hazards  of  adverse  gastrointestinal  (GI)  reactions
9.  The 
development of oral sustained-release formulations of this drug is 
highly desirable
10, in order to achieve improved therapeutic efficacy 
and patient compliance. In this study different brands of Diclofenic 
Sodium SR tablets were tested for their physical perameters and in-
vitro release study 
MATERIALS AND METHOD 
Five brands of Diclofenac Sodium SR tablets were purchased from 
the  local  market  and  were  tested  through  various  physical  and 
chemical methods such as, Weight variation, Diameter, Thickness, 
Hardness, Friability, Dissolution and Assay. 
Weight Variation: 
20  tablets  were  selected  randomly  and  weighed  individually.  The 
average weight was calculated and individual weight was compared 
to the average weight. The tablet passes the test according to British 
Pharmacopoeia  if  not  more  than  two  of  the  individual  weights 
deviate from the average weight by more than ± 7.5% and for one 
product limit was ± 5.0 %
11. 
Diameter 
In BP the stated diameter can deviate by ± 5% up to 12.5 mm and by 
± 3% above 15mm. Using Diameter Tester, Pharma Tester, and the 
diameter of 10 tablets ware determined
19. 
Thickness 
Thickness of tablet can fluctuate without any change in its weight 
because of variation in the granules density, pressure and Speed of 
tableting  machine.  Tablet  thickness  was  determined  by  Pharma 
Tester that measures the thickness in millimeters. Allowed Limit is ± 
5 %, depending on the size of the tablet
11. 
Hardness 
Tablet hardness depends on pressure applied, dwell time and nature 
of formulation. Hardness of 10 tablets was measured by the Pharma 
Tester
11. 
Friability 
The  friability  test  shows  the  abrasion  tendency  of  tablet  during 
manufacturing and supply process. For this purpose 20 tablets were 
selected  randomly  and  weighed  individually,  then  placed  in  the 
friabilator. It was then operated for 100 revolutions. The tablets were 
then  dusted, reweighed  and  percent  loss  was  calculated. Allowed 
Limit is not more than 1% of the weight of the tablets being tested
11. 
Assay 
Tablet contain specific amount of active ingredients with allowable 
variable  limit.  Assay  of  tablet  ensure  active  drug  and  stability  of 
product.  20 tablets were weighed, powdered and equivalent to 50 Muhammad Asif Khan et al. IRJP 2011, 2 (11), 81-84 
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mg  of  Diclofenac  sodium  powdered  was  weighed  and  dissolved 
in100  ml  volumetric  flask  using  0.1  N  NaOH.  The  solution  was 
filtered and 2 ml of this sample solution was taken and dissolved 
in100  ml  volumetric  flask  by  0.1N  NaOH.  Absorbance  was 
measured  at  276  nm  using  0.1  N  NaOH  as  a  blank  by 
spectrophotometer  and  percent  purity  was  determined
13.
 
Diclofenac Sodium % =  Abs. of sample x Wt. of   Std.  x   Av. Wt. of tablet    x 100 
Abs. of Std.   x   Wt. of sample 
 
Dissolution 
Dissolution test evaluate factors that affect the bioavailability of a 
drug from a solid dosage form. During dissolution test drug passes 
into solution is studied as a function of time and thus describes the 
over  all rate  of  drug release.  The  dissolution  test  was  conducted 
using  simulated  gastric  fluid  (0.1N  HCl)  and  intestinal  fluid 
(phosphate buffer pH 6.8) as dissolution medium. Using simulated 
gastric  fluid,  900  ml  of  0.1N  HCl  was  placed  in  the  vessel  and 
allowed to come to 37 ± 0.5°C. Then, Diclofenac sodium tablets 
were placed in all the six vessels, one in each vessels and stirrer was 
rotated  at  100  rpm  for  2  hrs.  At  the  end  of  2  hrs,  tablets  were 
removed  from  each  vessel  and  immediately  placed  in  900  ml  of 
phosphate buffer (pH 6.8) at same rotation speed and temperature as 
mentioned above for 8 hrs.  After predetermined intervals of  2, 4, 6 
and 8 hrs, sample of 10 ml was pipetted out and same volume of 
fresh phosphate buffer was added to keep volume of the dissolution 
medium  constant.  The  sample  was  diluted  to  100  ml  and  the 
absorbance was measured at 276 nm and dissolution was calculated 
using  Beer’s  Lambert  law.  Similarly,  the  absorbance  of  known 
concentration  of  standard  solution  of  Diclofenac  sodium  was 
measured and percent drug release was calculated
12,13. 
Data analysis: Data for weight uniformity test, diameter, thickness, 
friability and hardness of the tablets were analyzed by determining 
the mean ± standard deviation. 
RESULTS AND DISCUSSION 
In current project physiochemical properties of the five  brands of 
Diclofenac  sodium  (50mg)  SR  tablet  were  evaluated  in  order  to 
identify the relative difference in quality parameters and its effect on 
the release of drug from the dosage form. 
Weight Variation 
The significance of this test is to ensure that the tablets in each lot 
are  within  appropriate  range  size  and  contents  are  calculated  on 
average tablet weight basis. From table 1 and figure 1, it is clear that 
all tablets are in the range except two tablets cross the upper limit 
(321,321mg) of product code AOV 001 and for product code DYD 
004  only  one  tablet  crosses  upper  limits  (199  mg).  The  possible 
reason  for  the  difference  in  weight  variation  may  be  due  to  the 
machine problem or the coating process
13  .
 
Table  1: Product code with Appearance, Expiry date, Relative price, Average weight,  diameter, thickness, hardness (mean ± s. d.), friability and assay % of 
the tablets 
Product 
Code No. 
Appearance  Expiry 
(years) 
Relative 
Price (%) 
Avg. 
weight 
(mg) 
Avg. 
diameter 
(mm) 
Avg. 
thickness 
(mm) 
Avg. 
hardness 
(N) 
Friability 
% 
Assay 
% 
AOV 001  Biconvex Film 
coated tablet 
5  100  305.000 
± 6.656 
8.27 
± 0.03 
0.864 
± 0.068 
14.87 
± 0.87 
0.06  97.310 
BEF 002  Triangular 
Biconvex film 
coated tablet 
3  51  222.550 
± 4.651 
6.16 
± 0.04 
0.390 
± 0.079 
80.52 
± 9.50 
0.22  102.531 
CID 003  Biconvex film 
coated tablet 
3  83  327.25 
± 6.528 
8.09 
± 0.03 
1.419 
± 0.100 
203.90 
± 22.24 
0.24  98.575 
DYD 004  Triangular 
biconvex film 
coated tablet. 
4  38  182.85 
± 7.721 
5.29 
± 0.02 
0.450 
± 0.073 
71.32 
± 21.74 
0.16  96.361 
EAF 005  Biconvex square 
film coated tablet. 
3  96  247.700 
± 7.721 
5.13 
± 0.01 
1.736 
± 0.037 
173.66 
± 12.35 
0.20  94.620 
 
Diameter and Thickness 
These are important for Blister/strip packaging. From table 1 and 
figure 2 it is clear that the diameter was in the range of 5.13 ± 0.01 
to 8.27 ± 0.03 mm. So the diameters of all the tablets are in the 
range (± 5%)  
From table 1 thickness was in the range of 0.390 ± 0.079 to 1.736 ± 
0.037 mm. From table 1 and figure 3 it is clear that the  thickness of 
product code AOV 001, three tablets cross lower limit (0.78, 0.79, 
0.81 mm) and one tablet cross upper limits (1.00 mm).For product 
code BEF 002, five tablets cross lower limit (0.27, 0.32, 0.33, 0.33, 
0.37  mm)  and  three  tablets  cross  upper  limits  (0.42,  0.45,  0.51 
mm).For product code CID 003, four tablets cross lower limit (1.30, 
1.32, 1.33, 1.34 mm) and two tablet cross upper limits (1.55, 1.58 
mm).For  product  DYD  004,  four  tablets  cross  lower  limit  (0.35, 
0.35, 0.39, 0.41 mm) and five tablets cross upper limits (0.48, 0.49, 
0.51, 0.52, 0.56 mm).For product EAF 005, the entire tablets are 
within the range. The possible reason for the difference in thickness 
may be due to weight variation, hardness variation or variation in the 
granules  density,  pressure  and  speed  of  tableting  machine  or  the 
coating process. 
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Hardness and Friability of the tablets 
From table 1 and figure 4 it is clear that the hardness all tablets is in 
the  range  of  14.87  ±  0.87  to  203.90  ±  22.24,  but  variation  exist 
among the tablets.  
From  table  1  and  figure  5  it  is  clear  that,  friability  of  the  five 
different brands is less than 0.25 %. Therefore, it complies the BP 
standards
12,14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissolution test 
Dissolution test is the measure of the amount of drug released in the 
dissolution medium within time. Dissolution test was carried out in 
six tablets of each brand. The % age drug released was analyzed in 
both 0.1 N HCl and in phosphate buffer (pH 6.8). From table 2 and 
figure 6 it is clear that for product code AOV 001 and BEF 002, the 
results are with in range. While for product code CID 003, the 1st 
limit is within the range but 2
nd   and 3
rd limit are below from lower 
limits and 4
th limit is very below from lower limit. For product DYD 
004, all the four limits are very below from lower limits. For product 
EAF 005, the entire six tablets were completely dissolved in the 1
st 
two hrs. The possible reason for this difference in dissolution rate 
may be due to difference in surface area of the drug particles
15 or the 
nature  of  excipients  used  or  the  formulation  process.  It  has  been 
shown  by  Abdou
16  that  dissolution rate  of  a  drug  can  be  altered 
significantly  with  various  adjuncts  manufacturing  process.
 
Table  2: Dissolution % of the tablets at different times 
Two 
hrs 
Limit 
%  
Code No. 
AOV001 
Code No. 
BEF002 
Code No. 
CID003 
Code No. 
DYD004 
Code No. 
EAF005 
1
st
 
15 - 30  17.84  24.67  15.75  6.976  97.41 
2
nd
 
25 – 50  30.686  39.006  22.47  10.486  --------- 
3
rd
 
35 - 70  44.314  49.77  28.57  14.83  --------- 
4
th
 
NLT 70  90.386  72.84  32.160  21.145  --------- 
Pharmaceutical Assay 
Using UV spectrophotometer, pharmaceutical assay was carried out 
for  all  the  five  brands  of  Diclofenac  sodium.  The  limit  of 
pharmaceutical  assay  according  to  the  specification  of  BP  is  90-
110%. From table 1 and figure 7 it is clear that the  pharmaceutical 
assay of the five different brands is within the range. Lowest content 
is 94.620 % while highest content 102.531 %. 
 
 
 
 
 
 
 
 
 
 
 
 
Expiry, Price and Appearance 
It  has  been  noted  during  the  present  study  that  there  is  a  lot  of 
difference in the price, expiry date and appearance of national and 
multinational pharmaceutical products. From table 1 it is clear that, 
the product code AOV 001 has the highest expiry date of 5 years 
while product code DYD 004 has the second highest expiry date of 4 
years and the remaining three products has the lowest expiry date of 
3  years.  On  the  other  hand,  the  product  code  AOV  001  has  the 
highest price with good quality, but product code BEF 002 has good 
quality with very low price, while the product code CID 003 and 
EAF  005  has  high  price  with  low  quality.  The  tablets  of  two 
products AOV 001, CID 003 are biconvex; while the tablets of two 
products BEF 002, DYD 004 are triangular biconvex and the tablets 
of EAF 005 are biconvex square. 
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CONCLUSION 
Close monitoring of different process in Pharmaceutical industries 
will reduce the production time and cost, as well as will improve the 
quality of the product. It was found that dissolution was the critical 
parameter where problem exist among different brands. Only two 
brands  passed  the  dissolution  test,  tablets  of  one  brand  were 
completely dissolved within 1st two hrs while remaining brands fail 
the dissolution test. Similarly problem was found in thickness of the 
different  brands.  However  no  major  problem  was  found  in tablet 
weight  variation, assay,  diameter,  friability  and hardness. Also,  it 
was  noted  that  some  of  the  local  firm  has  very  low  price  as 
compared to the multinational firm having the same good quality but 
some local firm has nearly the same price as that of multinational 
with low quality. It was concluded that the different brands of well 
reputed local  pharmaceutical  firms  can  be  compared  with  that  of 
multinational  firms,  however  products  of  some  less  known  local 
firms needs improvement in quality but some local firm should be 
strictly monitored for manufacturing of control release dosage form. 
This study also infancies the need for constant market monitoring of 
new  products  to  ascertain  their  equivalency  to  the  innovator 
products. 
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